MONTEROSA: Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study

Sponsor
Azienda Ospedaliera Città della Salute e della Scienza di Torino (Other)
Overall Status
Unknown status
CT.gov ID
NCT04403659
Collaborator
Santer Reply S.p.A. Milan, Italy (Other), Caretek S.r.l. Turin, Italy (Other)
50
1
2
8
6.2

Study Details

Study Description

Brief Summary

"La Casa nel Parco" (CANP) Project is a multidisciplinary project funded by the European Union and Regione Piemonte aimed to explore innovative technology application in the care of older subjects. In this context, MONTEROSA is a monocentric randomized controlled open-label clinical trial evaluating the use of a telemonitoring/telemedicine (TM) suite (including a sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph) as a support to the routine clinical care of patients admitted to a Hospital at Home service for acute decompensated heart failure.

The main objective of the study will be to evaluate the impact of TM on number of daily physician's visits. Secondary objectives will be to evaluate the impact of TM on number of daily nurse visits, on overall in-hospital mortality and on patient's and caregiver's quality of life.

Condition or Disease Intervention/Treatment Phase
  • Device: Telemedicine/telemonitoring (TM) suite
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Monitoraggio Telematico di Pazienti Ricoverati in Ospedalizzazione a Domicilio Per Scompenso Cardiaco Acuto - Studio Pilota
Anticipated Study Start Date :
Jun 1, 2020
Anticipated Primary Completion Date :
Jan 31, 2021
Anticipated Study Completion Date :
Jan 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Use of a telemonitoring/telemedicine suite (including a sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph) as a support to the routine clinical care

Device: Telemedicine/telemonitoring (TM) suite
The couples patient/caregiver will receive and trained to use a suite of TM instruments including: sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph. During the intervention phase (i.e. from allocation to exit from the study), the caregiver/patient will be asked to measure twice daily, at prespecified times, the following parameters using TM devices: arterial blood pressure, peripheral arterial haemoglobin saturation, tympanic temperature. Body weight will be evaluated once daily. The TM glucometer and TM electrocardiograph will be used exclusively by healthcare staff in case of patients in need of capillary blood glucose testing and according to clinical needs, respectively. All data will be automatically sent to a central interface and made readily available to physicians and nurses, to enable a prompt clinical response. In case of malfunctioning, a technical support will be ensured.

No Intervention: Control

Routine clinical care, following European Society of Cardiology 2016 Guidelines on Heart failure and Good Clinical Practice guidelines

Outcome Measures

Primary Outcome Measures

  1. Mean daily number of physician visits [From allocation through to HaH discharge, in mean 15 days]

    Mean daily number of physician visits during Hospital at Home (HaH) stay, defined as total number of physician visits during HaH stay, divided by days of HaH stay, for every single patient

Secondary Outcome Measures

  1. Mean daily number of nurse visits [From allocation through to HaH discharge, in mean 15 days]

    Mean daily number of nurse visits during Hospital at Home (HaH) stay, defined as total number of nurse visits during HaH stay, divided by days of HaH stay, for every single patient

  2. Mean daily number of urgent physician visits [From allocation through to HaH discharge, in mean 15 days]

    Mean daily number of urgent physician visits during Hospital at Home (HaH) stay, defined as total number of urgent (i.e. unplanned) physician visits during HaH stay, divided by days of HaH stay, for every single patient

  3. Mean daily number of urgent nurse visits [From allocation through to HaH discharge, in mean 15 days]

    Mean daily number of urgent nurse visits during Hospital at Home (HaH) stay, defined as total number of urgent (i.e. unplanned) nurse visits during HaH stay, divided by days of HaH stay, for every single patient

  4. Overall mortality [From allocation through to HaH discharge, in mean 15 days]

    Death by any cause during Hospital at Home (HaH) stay

  5. Patient's quality of life evaluated through the 12-Item Short Form survey (SF-12) [At HaH discharge, in mean 15 days after allocation]

    Patient's quality of life evaluated through the 12-Item Short Form survey (SF-12), stratified in Physical component summary (Pcs) and Mental component summary (Mcs), at Hospital at Home (HaH) discharge

  6. Main caregiver's quality of life evaluated through the 12-Item Short Form survey (SF-12) [At patient's HaH discharge, in mean 15 days after allocation]

    Main caregiver's quality of life evaluated through the 12-Item Short Form survey (SF-12), stratified in Physical component summary (Pcs) and Mental component summary (Mcs), at Hospital at Home (HaH) discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient admitted in Hospital at Home with signs and/or symptoms of new-onset or decompensated heart failure, according with the definition of 2016 European Society of Cardiology (ESC) guidelines on Heart Failure

  • Written informed consent signed by both the patient and the main caregiver

Exclusion Criteria:
  • Main caregiver with low IT skills (e.g. unable to use a smartphone);

  • Patient in whom body weight or accurate daily urine output cannot be measured

  • Patient with history of neoplastic/degenerative disease and with estimated life expectancy less than 3 months

  • Patient with decompensated liver cirrhosis (Child-Pugh score B o C)

Contacts and Locations

Locations

Site City State Country Postal Code
1 S.C. Geriatria e Malattie Metaboliche dell'Osso U, A.O.U. Città della Salute e della Scienza di Torino Torino TO Italy 10126

Sponsors and Collaborators

  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
  • Santer Reply S.p.A. Milan, Italy
  • Caretek S.r.l. Turin, Italy

Investigators

  • Principal Investigator: Renata Marinello, MD, PhD, OAU Città della Salute e della Scienza di Torino, Turin, Italy

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dott.ssa RENATA MARINELLO, Principal Investigator, Azienda Ospedaliera Città della Salute e della Scienza di Torino
ClinicalTrials.gov Identifier:
NCT04403659
Other Study ID Numbers:
  • MONTEROSA
First Posted:
May 27, 2020
Last Update Posted:
May 27, 2020
Last Verified:
May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dott.ssa RENATA MARINELLO, Principal Investigator, Azienda Ospedaliera Città della Salute e della Scienza di Torino
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2020